Viking Therapeutics(VKTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 • Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 • Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLD • Positive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductio ...